To study and potentially model DRAM2-retinopathy, we used knockdown or knockout in cells or mice, whereas patients carry point mutations in DRAM2. This choice was based on findings suggesting that patients with at least one loss-of-function variant present with earlier disease onset compared to patients carrying only missense or in-frame deletions (Sergouniotis et al., 2015). This evidence concerns the gene DRAM2 and retinal disorder.